Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AION-301 in Stage 3 Chronic Kidney Disease
NCT06721143Phase 2Recruiting
- Sponsor
- AION Healthspan
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Rejuvxl in chronic kidney disease (CKD), sponsored by AION Healthspan. Started Jan 2025; status: recruiting.
02
Drugs
Rejuvxl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06721143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721143.